| 2.91 -0.42 (-12.61%) | 12-12 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.85 | 1-year : | 25.11 |
| Resists | First : | 13.57 | Second : | 21.5 |
| Pivot price | 10.22  |
|||
| Supports | First : | 0.75 | Second : | 0.63 |
| MAs | MA(5) : | 2.88 |
MA(20) : | 12.11 |
| MA(100) : | 20.08 |
MA(250) : | 20.27 |
|
| MACD | MACD : | -4.4 |
Signal : | -3.4 |
| %K %D | K(14,3) : | 15.6  |
D(3) : | 13 |
| RSI | RSI(14): 25.3 |
|||
| 52-week | High : | 43.4 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NLSP ] has closed above bottom band by 22.4%. Bollinger Bands are 184.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.5 - 3.53 | 3.53 - 3.55 |
| Low: | 3.13 - 3.15 | 3.15 - 3.17 |
| Close: | 3.32 - 3.36 | 3.36 - 3.39 |
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Wed, 29 Oct 2025
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem - PR Newswire
Wed, 29 Oct 2025
NLS Pharmaceutics AG (NLSP) Stock: Plunges 15% Amid Nasdaq-Approved Merger with Kadimastem - parameter.io
Tue, 30 Sep 2025
NLS Pharmaceutics stock tumbles after merger approval with Kadimastem - Investing.com
Tue, 30 Sep 2025
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting - PR Newswire
Mon, 30 Jun 2025
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing - PR Newswire
Tue, 05 Nov 2024
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 19.4 (%) |
| Held by Institutions | 5.8 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -17.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.23 |
| PEG Ratio | 0 |
| Price to Book value | 0.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|